Kite Readies A Second CAR-T For Filing As CD19 Competition Grows
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
You may also be interested in...
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
The latest drug development news and highlights from our US FDA Performance Tracker.